Page 3 - Cambrian Bio News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cambrian bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cambrian Bio Today - Breaking & Trending Today

What Is A Longevity Biotechnology Company?

There are many companies claiming to be in longevity biotechnology. But which ones qualify as longevity biotechnology companies? ....

United States , Alex Comfort , James Peyer , Kristen Fortney , Stephens Hall , Michael West , Alexander Bogdanov , Jim Mellon , Risa Starr , A Longevity Biotechnology Company , Paulf Glenn Center , A Checklist For Longevity Biotechnology Companies , Longevity Vision Fund , Apollo Health Ventures , Geron Corporation , Longevity Biotechnology Association , American Federation For Aging Research , Aging Research , Drug Discovery , Chasing The Dream , Human Life , Longevity Biotechnology , American Federation , Bertram Endeavours , Bioage Labs , Cambrian Bio ,

Oviva Therapeutics Appoints Rachel Rimsky Rubin as Chief Operating Officer

/PRNewswire/ Oviva Therapeutics, a premier biotech company dedicated to addressing the vast unmet need in women s health by developing first-in-class. ....

Daisy Robinton , Bio Pipeco , Rachel Rimsky Rubin , Roivant Health , Oviva Therapeutics Inc , Deutsche Bank , Pipeline Company Pipeco , Roivant Sciences , Goldman Sachs , Cornell University , Chief Operating Officer , Vice President , Roivant Social , Alternative Investments , Manager Selection , Cambrian Bio Pipeco , Pipeline Company , Cambrian Bio , Oviva Therapeutics ,

This UTSW Graduate Wants to Lengthen Your Lifespan One Disease at a Time

Cambrian Bio is developing treatments that give us more healthy years. ....

New York , United States , James Peyer , Sean Morrison , Research Institute Of Texas , Cambrian Bio , Cancer Prevention , Research Institute , Cambrian Bio Founder , Chairman James Peyer , Amplifier Therapeutics ,

Arcellx Raises $115M in Series C Financing

Arcellx, a Gaithersburg, Md.-based clinical-stage biopharmaceutical company advancing a pipeline of adaptive and controllable cell therapies, raised $115m in Series C financing.
The round was co-led by Samsara BioCapital and CAM Capital, joined by new investors Adage, Asymmetry, CaaS Capital, Cambrian Bio, Sixty Degree, Soleus Capital, Surveyor Capital (a Citadel company), Suvretta, and Terra Magnum Capital Partners, and existing investors NEA, Novo Holdings, SR One, Takeda Ventures, LG Tech, and Clough Capital.
The company intends to use the funds to develop CART-ddBCMA, a BCMA-specific CAR-modified T-cell therapy currently in Phase 1 and anticipated to begin a pivotal trial in 2022, and initiate clinical trials evaluating ACLX-001 and ACLX-002, cell therapies derived from its controllable ARC-SparX platform, in multiple myeloma (MM) and acute myelogenous leukemia (AML), respectively. ....

Novo Holdings , Samsara Biocapital , Caas Capital , Cambrian Bio , Sixty Degree , Soleus Capital , Surveyor Capital , Terra Magnum Capital Partners , Takeda Ventures , Rami Elghandour , Chief Executive Officer , நோவோ ஹோல்டிங்ஸ் , சாஸ் மூலதனம் , அறுபது பட்டம் , நிலமளப்போர் மூலதனம் , டெர்ரா மகத்தானது மூலதனம் கூட்டாளர்கள் , டாகேடா முயற்சிகள் , தலைமை நிர்வாகி அதிகாரி ,